Effect of photodynamic therapy in combination with mitomycin C on a mitomycin-resistant bladder cancer cell line.

Photodynamic therapy is a method for treating cancer using drugs activated by light. A new compound, 5-aminolaevulinic acid (ALA), is a precursor of the active photosensitizer protoporphyrin IX (PpIX) and has fewer side-effects and much more transient phototoxicity than previous photosensitizers. Cell survival of ALA-mediated photodynamic therapy was measured in the J82 bladder cancer cell line, along with its mitomycin C-resistant counterpart J82/MMC. This demonstrated that mitomycin resistance is not cross-resistant to photodynamic therapy. There was also a suggestion that the mitomycin-resistant cells were more susceptible to photodynamic therapy than the parent cell line. Photodynamic therapy appeared to enhance the effect of mitomycin C, when mitomycin C was given first. This phenomenon was apparent for both drug-resistant and drug-sensitive cell lines. This suggests a possible role for combined mitomycin C and photodynamic therapy in superficial bladder tumours that have recurred despite intravesical cytotoxic drug treatment.

[1]  A. J. MacRobert,et al.  Oral versus intravenous administration of 5-aminolaevulinic acid for photodynamic therapy. , 1993, British Journal of Cancer.

[2]  Shivendra V. Singh,et al.  Characterization of a human bladder cancer cell line selected for resistance to mitomycin C , 1994, International journal of cancer.

[3]  Michele T. Cooper,et al.  Cutaneous phototoxic occurrences in patients receiving Photofrin® , 1990, Lasers in surgery and medicine.

[4]  W. Szybalski,et al.  A MOLECULAR MECHANISM OF MITOMYCIN ACTION: LINKING OF COMPLEMENTARY DNA STRANDS. , 1963, Proceedings of the National Academy of Sciences of the United States of America.

[5]  J. Ordonez,et al.  Estimation of cell survival by flow cytometric quantification of fluorescein diacetate/propidium iodide viable cell number. , 1989, Cancer research.

[6]  H. Oppelaar,et al.  Enhancement of interstitial photodynamic therapy by mitomycin C and EO9 in a mouse tumour model , 1994, International journal of cancer.

[7]  D. Newling,et al.  A phase II study of intravesical mitomycin C in the treatment of superficial bladder cancer. , 1984, British journal of urology.

[8]  J. Winfield,et al.  In vitro and in vivo cytotoxicity of gossypol against central nervous system tumor cell lines. , 1994, Journal of neuro-oncology.

[9]  R. Riesenberg,et al.  Photodynamic effects of 5-aminolevulinic acid-induced porphyrin on human bladder carcinoma cells in vitro. , 1996, European journal of cancer.

[10]  J. Moan,et al.  The mechanism of photodynamic inactivation of human cells in vitro in the presence of haematoporphyrin. , 1979, British Journal of Cancer.

[11]  W. Star,et al.  Destruction of rat mammary tumor and normal tissue microcirculation by hematoporphyrin derivative photoradiation observed in vivo in sandwich observation chambers. , 1986, Cancer research.

[12]  W. Szybalski,et al.  Mitomycins and Porfiromycin: Chemical Mechanism of Activation and Cross-linking of DNA , 1964, Science.

[13]  J. Kennedy,et al.  In vitro studies on the potential use of 5-aminolaevulinic acid-mediated photodynamic therapy for gynaecological tumours. , 1996, British Journal of Cancer.

[14]  H. Oppelaar,et al.  Enhancement of photodynamic therapy by mitomycin C: a preclinical and clinical study. , 1996, British Journal of Cancer.

[15]  N. Bachur,et al.  NADPH cytochrome P-450 reductase activation of quinone anticancer agents to free radicals. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[16]  R Baumgartner,et al.  Early clinical experience with 5-aminolevulinic acid for the photodynamic therapy of superficial bladder cancer. , 1996, British journal of urology.

[17]  J C Kennedy,et al.  Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. , 1992, Journal of photochemistry and photobiology. B, Biology.

[18]  J. Kennedy,et al.  Using δ-Aminolevulinic Acid in Cancer Therapy , 1994 .

[19]  S. Britton,et al.  Blood flow in transplantable bladder tumors treated with hematoporphyrin derivative and light. , 1984, Cancer research.

[20]  Cytotoxicity and cytokinetic effects of mitomycin C and/or photochemotherapy in a human colon adenocarcinoma cell line. , 1992, The International journal of biochemistry.

[21]  J Moan,et al.  Potentiation of photodynamic therapy by mitomycin C in cultured human colon adenocarcinoma cells. , 1993, Radiation research.

[22]  A. Batlle,et al.  Porphyrins, porphyrias, cancer and photodynamic therapy--a model for carcinogenesis. , 1993, Journal of photochemistry and photobiology. B, Biology.

[23]  T. Wieman,et al.  Complications of whole bladder dihematoporphyrin ether photodynamic therapy. , 1989, The Journal of urology.

[24]  N. Bachur,et al.  A general mechanism for microsomal activation of quinone anticancer agents to free radicals. , 1978, Cancer research.

[25]  M. Berns,et al.  TUMOR DESTRUCTION IN PHOTODYNAMIC THERAPY , 1987, Photochemistry and photobiology.

[26]  D. Phillips,et al.  What are the ideal photoproperties for a sensitizer? , 1989, Ciba Foundation symposium.

[27]  T. Dougherty,et al.  Autoradiographic distribution of hematoporphyrin derivative in normal and tumor tissue of the mouse. , 1981, Cancer research.

[28]  A. Richter,et al.  Dye-mediated photolysis is capable of eliminating drug-resistant (MDR+) tumor cells. , 1993, Blood.

[29]  T. Dougherty.  Photodynamic therapy. , 1993, Photochemistry and photobiology.

[30]  D. Newling,et al.  Intravesical mitomycin C for the treatment of recurrent superficial bladder tumours. , 1987, British journal of urology.

[31]  R. Keck,et al.  MORPHOLOGICAL CHANGES OF TUMOR MICROVASCULATURE FOLLOWING HEMATOPORPHYRIN DERIVATIVE SENSITIZED PHOTODYNAMIC THERAPY * , 1987, Photochemistry and photobiology.